AstraZeneca plc: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors
• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• AstraZeneca: PharmaVitae forecasts at a glance
• Strategic insight
  • Acquisition of MedImmune
  • Blockbuster-centric growth model
  • Exposure to generic competition to intensify
  • Lack of new product launches damages integrity of blockbuster strategy
  • Cost control essential to retain hope of profit growth
  • Outlook
• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Product developments
• Deals and alliances
  • Technology deals
• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• M&A history
  • Subsequent M&A activity
  • M&A strategy

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14
• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
  • Launch/core/expiry configuration, 2008 - 14
• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
• Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Overview
• Cardiovascular
  • Crestor
  • Brilinta
• Oncology
  • Arimidex
• Gastrointestinal
  • Nexium
• Central Nervous System
  • Seroquel
• Respiratory
  • Symbicort
  • Pulmicort
• Infectious diseases
  • Numax
  • Synagis
• Endocrinology
  • Onglyza

APPENDIX

• R&D pipeline
• Abbreviations
• Exchange rates

TABLES

• Table: AstraZeneca - PharmaVitae forecasts at a glance
• Table: AstraZeneca key product developments, Q1-Q2 2009
• Table: AstraZeneca product deals and alliances, Q1-Q2 2009
• Table: AstraZeneca technology deals and alliances, Q1-Q2 2009
• Table: AstraZeneca M&A activity, Q1-Q2 2009
• Table: AstraZeneca company announcements, Q1-Q2 2009
• Table: AstraZeneca future product milestones, 2009 - 11
• Table: AstraZeneca product portfolio overview ($m), 2002 - 08
• Table: AstraZeneca product portfolio overview ($m), 2008 - 14
• Table: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: AstraZeneca launch portfolio overview ($m), 2008 - 14
• Table: AstraZeneca core portfolio overview ($m), 2008 - 14
• Table: AstraZeneca expiry portfolio overview ($m), 2008 - 14
• Table: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: AstraZeneca prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total AstraZeneca sales by business unit ($m), 2002 - 08
• Table: AstraZeneca operating revenue/cost analysis ($m), 2002 - 08
• Table: AstraZeneca operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: AstraZeneca operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: AstraZeneca operating revenue/cost analysis ($m), 2008 - 14
• Table: AstraZeneca Key products overview
• Table: Crestor: overview
• Table: Crestor: sales forecast ($m), 2008 - 14
• Table: Brilinta: overview
• Table: Brilinta: sales forecast ($m), 2008 - 14
• Table: Arimidex: overview
• Table: Arimidex: sales forecast ($m), 2008 - 14
• Table: Nexium: overview
• Table: Nexium: sales forecast ($m), 2008 - 14
• Table: Seroquel: overview
• Table: Seroquel: sales forecast ($m), 2008 - 14
• Table: Symbicort: overview
• Table: Symbicort: sales forecast ($m), 2008 - 14
• Table: Pulmicort: overview
• Table: Pulmicort: sales forecast ($m), 2008 - 14
• Table: Numax: overview
• Table: Numax: sales forecast ($m), 2008 - 14
• Table: Synagis: overview
• Table: Synagis: sales forecast ($m), 2008 - 14
• Table: Onglyza: overview
• Table: Onglyza: sales forecast ($m), 2008 - 14
• Table: AstraZeneca R&D pipeline (Phase I-Phase III)
• Table: Exchange rates, 2009

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: AstraZeneca' s financial performance ($m), 2002 - 14
• Figure: AstraZeneca prescription pharmaceutical sales growth by portfolio component (blockbusters, rest of portfolio, new launches) ($m), 2002-14
• Figure: AstraZeneca 2008 prescription pharmaceutical sales by global launch year ($m)
• Figure: AstraZeneca absolute change in sales by portfolio component ($m), 2008-14
• Figure: AstraZeneca operating revenue/cost analysis ($m), 2002 - 14
• Figure: AstraZeneca SWOT analysis
• Figure: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: AstraZeneca Key product sales ($m), 2002 - 14
• Figure: AstraZeneca key sales growth drivers and resistors ($m), 2002 - 08
• Figure: AstraZeneca key sales growth drivers and resistors ($m), 2008 - 14
• Figure: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: AstraZeneca launch/core/expiry configuration ($m), 2008 - 14
• Figure: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: AstraZeneca prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: AstraZeneca operating revenue/cost analysis ($m), 2002 - 14